Reviews/Chronic Pain Pharmacotherapy/Duloxetine plus pregabalin in neuropathy
Ant · CPP-ANT-02 · v2
Two randomised trials in this corpus tested adding duloxetine and pregabalin together rather than using one alone. The largest, in people with painful diabetic nerve damage [15], found that patients who still had pain on a single drug got more relief when the second drug was added than those who stayed on one drug. A second, independent trial found the combination beat each single drug for overall pain relief, but it was done in fibromyalgia rather than classic nerve pain [16]. A mouse study pointed the same way but tested three drugs together, not just the two in the claim [21]. The direction of the evidence is consistent across these studies, which is why the panel supported the claim, but no study here compares the two-drug combination head-to-head against each single drug from the start in nerve pain, so the panel did not treat it as settled.
In the largest double-blind randomised crossover trial in diabetic peripheral neuropathic pain, pain reduction was greater for patients moved onto combination therapy than for those who remained on monotherapy (1·0 vs 0·2 on the 0-10 scale) [15]. An independent randomised double-blind crossover trial reported that the pregabalin-duloxetine combination gave more moderate-or-better global pain relief than either single drug (68% vs 39% for pregabalin and 42% for duloxetine), though this was in fibromyalgia [16]. A mouse study of a pregabalin, duloxetine and tramadol mixture showed added benefit on allodynia [21]. All three point in the same direction, but each has a scope limit: the comparison in [15] is secondary, [16] is an off-population, and [21] is preclinical and three-drug. The contested point: The division is whether 'improves over monotherapy' is actually demonstrated or only suggested. In [15] the primary result was that the three pathways and their monotherapies had similar efficacy, and the combination-over-monotherapy benefit (1·0 vs 0·2) came from a secondary, non-randomised contrast of patients who needed supplementation against those who stayed on one drug.
All 33 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Chronic Pain Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
OPTION-DM's primary finding was that the three pathways and their monotherapies had similar efficacy; the combination-over-monotherapy result (1·0 vs 0·2) is a secondary, non-randomised comparison of patients who needed supplementation against adequate responders who stayed on monotherapy, carrying selection and indirectness risk.
Gilron 2016 is fibromyalgia, a nociplastic condition not classic neuropathic pain, its primary daily-pain outcome was significant only versus placebo and pregabalin (not versus duloxetine), and n=41 is small — limited external validity for the neuropathic-pain claim.
Where it remains uncertain. The combination-over-monotherapy result in [15] is a secondary, non-randomised comparison, and the one clean combination-beats-both-monotherapies result [16] is in fibromyalgia rather than classic neuropathic pain.
Aleatory
The combination signal rests on modest numbers: 130 analysed in [15] and only 41 randomised in [16], leaving the estimates vulnerable to chance variation.
Epistemic
No corpus study randomises patients to combination versus each monotherapy from the start in neuropathic pain, so the magnitude of any combination advantage is unmeasured here.
Inferential
Extending [16] to the claim assumes a nociplastic condition behaves like classic neuropathic pain, which the corpus does not establish.
The load-bearing papers from a corpus of 33, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary RCT in genuine neuropathic pain (DPNP) showing combination outperforms monotherapy in suboptimal responders.
“Combination treatment was well tolerated and led to improved pain relief in patients with suboptimal pain control with a monotherapy.”
Panel auditInternal validity: high · scope of inference: Adults with diabetic peripheral neuropathic pain and suboptimal monotherapy response; combination includes but is not limited to duloxetine plus pregabalin.Key limitations: combination result pools pathways not D-P alone · no p-value or CI given for the combination-vs-monotherapy contrast · crossover, DPNP only
Independent RCT showing du+preg combination superior to each monotherapy on global pain relief (off-population: fibromyalgia).
“Participants (%) reporting ≥moderate global pain relief were 18%, 39%, 42%, and 68%, respectively (P < 0.05 for combination vs placebo, pregabalin, and duloxetine).”
Panel auditInternal validity: medium · scope of inference: Fibromyalgia, a nociplastic pain syndrome distinct from neuropathic pain.Key limitations: wrong population for the claim · small sample · crossover
Preclinical support for combination analgesia; weakened by triple-drug design and animal model.
“The combination of pregabalin, duloxetine, and tramadol significantly alleviated mechanical hyperalgesia in mice with CPIP and SNL.”
Panel auditInternal validity: low · scope of inference: Mouse models of neuropathic pain (CPIP, SNL).Key limitations: preclinical · tramadol included · D+P pairing not isolated
3 of 33 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent primary RCT evidence supports the combination, but the decisive head-to-head combination-versus-monotherapy comparison is only partial and partly off-population.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No from-randomisation 3-arm neuropathic-pain RCT. The claim's 'improves over monotherapy' is never tested as a primary, randomised combination-versus-each-monotherapy comparison in neuropathic pain in this corpus; [15] supplies it only as a secondary contrast. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective double-blind trial randomising neuropathic-pain patients to du+preg combination, duloxetine monotherapy, and pregabalin monotherapy from baseline, with pain reduction as the primary endpoint.
Open question: Does the duloxetine+pregabalin combination reduce pain more than either drug alone when patients are randomised to combination or monotherapy from the start in neuropathic pain? Why it is still open: In [15] the combination-versus-monotherapy comparison is secondary and non-randomised, and the primary result found the pathways and monotherapies similarly effective; no parallel 3-arm neuropathic-pain RCT exists in the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19